Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single And Multiple Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Healthy Chinese Subjects.

Next Previous
Trial Profile

An Open Label, Single And Multiple Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Healthy Chinese Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Crohn's disease; Plaque psoriasis; Renal transplant rejection; Rheumatoid arthritis; Ulcerative colitis
  • Focus Pharmacokinetics

Most Recent Events

  • 15 Mar 2017 According to a Pfizer media release, based on the phase 3 Oral Rheumatoid Arthritis triaLs (ORAL) global development program including China subgroup study (A3921046) and pharmacokinetic study (A3921065) the Chinese Food and Drug Administration (CFDA) has approved XELJANZ for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX).
  • 01 Sep 2015 Results published in the Clinical Pharmacology in Drug Development
  • 15 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top